Swedish medtech startup Multi4 has successfully raised SEK 29 million (approximately €2.6 million / $3 million) in a new funding round, reinforcing investor confidence in its mission to transform cancer diagnostics and treatment.
Driving Innovation in Cancer Care
Based in Jönköping, Multi4 is developing advanced technology for endoscopic cancer diagnosis and treatment. The company aims to significantly improve how cancers are detected and treated—making procedures more precise, less invasive, and ultimately more effective for patients.
The fresh capital injection will accelerate product development and bring the company closer to clinical adoption, a critical milestone in the highly regulated medtech space.
Strong Backing from Experienced Investors
The round includes continued support from existing investors, alongside a group of prominent new angel investors with deep expertise across healthcare, medtech, and business scaling.
Notable new investors include:
- Per Langoe – bringing extensive experience in medical technology and urology, including work with Palette Life Sciences
- Emil Billbaeck – former CEO of Bonesupport, who has already supported Multi4 as an advisor
- Joachim Arcari and Hans Cappelen Arnesen – strengthening the company’s commercial capabilities
- Martin Zetterlund, along with Helena von Knorring and Hans von Knorring – contributing both healthcare insight and strategic business experience
The addition of such a diverse and experienced investor group signals strong belief in Multi4’s long-term potential and the relevance of its technology in modern oncology.
A Vote of Confidence in DeepTech Healthcare
Attracting both capital and high-caliber expertise is a major validation for early-stage healthtech companies. In Multi4’s case, this funding round highlights not only the strength of its innovation but also the urgency of improving cancer care globally.
With cancer remaining one of the leading causes of death worldwide, advancements in early detection and minimally invasive treatment methods are critical. Multi4’s approach—leveraging cutting-edge endoscopic technology—positions it at the intersection of precision medicine and scalable healthcare innovation.
What’s Next
With this new funding, Multi4 is set to move into its next phase of growth—focusing on further development, validation, and preparing its technology for broader clinical use.
As the company continues to evolve, its mission remains clear: to make a real, measurable difference for cancer patients and healthcare systems alike.
